IL-ADVANCED-CLINICAL
Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Andreas Amrein has joined the Executive Team as Senior Vice President of Asia-Pacific (APAC) and Japan as well as Managing Director for Europe and Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308006375/en/
Dr. Amrein will be instrumental to the organization’s continued expansion and strengthening of Advanced Clinical’s current operations into the APAC region, which include offices in Singapore, Australia and Japan. He’ll also oversee development and expansion opportunities for additional locations across Europe and Canada, complementing the company’s existing footprint inclusive of 10 office locations in Europe as well as an office in Toronto, Canada.
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies, including Fortune 100 companies (Novartis, Abbott and Shire) and dynamic start-ups.
“From my specialization in rapid commercial expansions, launches, transformations, partnerships and more across Asia and around the globe, I look forward to leveraging my knowledge to help Advanced Clinical further establish quality operations internationally,” said Dr. Amrein.
“We are excited to have Andreas on our team as we continue to expand into the APAC region and Japan,” said Julie Ross, President of Advanced Clinical. “Andreas will be instrumental in accelerating business growth as we diversify our global clinical programs and elevate our clinical strategy for the clients and patients we serve. After our successful entry into the region in 2021 combined with additional APAC office openings planned for 2022, Andreas will undoubtedly help elevate our presence across the APAC, European and Canadian regions as a global leader in clinical research, FSP and strategic resourcing services.”
About Advanced Clinical
Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006375/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 15:10:00 CEST | Press release
65 Dental Practices Demonstrate Clear ROI With a Clinician-Designed AI Workflow: Zero Missed Calls, Reduced Frontline Workload, Faster Patient Care and Measurable Returns at ScaleThe Results Build on Wildix’s Recent Launch of Wilma AI, the Embedded Agentic AI Layer Behind its Secure, Scalable UCaaS Platform Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed S
KBS Partners with Rimini Street to Accelerate its AI Vision17.9.2025 15:00:00 CEST | Press release
Korea’s public broadcasting network prioritizes funding new AI initiatives instead of costly SAP upgrades by leveraging Rimini Support™ for SAP Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Korean Broadcasting System (KBS) has partnered with Rimini Street to provide support for its SAP ECC 6.0, a strategic move that has helped to fund and accelerate its AI vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917964406/en/ KBS Partners with Rimini Street to Accelerate its AI Vision Central to KBS’s AI-enabled future is the valuable data stored in its core SAP system, a source that encompasses more than 20 years of information unique to the organization. Drawing upon this rich resource, KBS plans to create multiple AI projects and ongoing
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom